Supernus Pharmaceuticals Inc (SUPN)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total current assets	US$ in thousands	493,113	449,360	423,538	883,340	734,151	663,886	625,120	568,516	601,590	668,375	639,244	586,023	630,417	552,015	557,153	557,048	472,644	427,082	390,911	419,967
Total current liabilities	US$ in thousands	290,196	287,534	252,590	731,545	687,958	725,987	735,536	284,558	315,379	234,711	283,447	240,812	245,108	299,606	269,276	168,335	160,587	149,717	143,971	151,706
Current ratio		1.70	1.56	1.68	1.21	1.07	0.91	0.85	2.00	1.91	2.85	2.26	2.43	2.57	1.84	2.07	3.31	2.94	2.85	2.72	2.77

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $493,113K ÷ $290,196K
= 1.70

Supernus Pharmaceuticals Inc's current ratio has shown fluctuations over the past eight quarters. The ratio has generally been above 1, indicating that the company has had more current assets than current liabilities to cover its short-term obligations.

In Q4 2023, the current ratio improved to 1.70 from 1.56 in Q3 2023, suggesting better liquidity and ability to meet short-term liabilities. This increase indicates that the company may have increased its current assets relative to its current liabilities.

Looking back at Q2 and Q1 2023, the current ratio was at 1.68 and 1.21 respectively. Although the ratio decreased in Q1 2023, it remained above 1, indicating the company's ability to cover its short-term obligations.

Compared to the same quarter in the previous year, the current ratio has shown significant improvement. In Q4 2022, the ratio was at 1.07, and there has been a steady upward trend since then. The most notable change was in Q1 2022, where the current ratio was at 2.00, reflecting potentially strong liquidity and an increased ability to repay short-term liabilities.

Overall, Supernus Pharmaceuticals Inc's current ratio has been above 1 in recent quarters, suggesting a healthy liquidity position. It is essential for the company to continue monitoring and managing its current assets and liabilities effectively to ensure it can meet its short-term financial obligations.